Lupin receives USFDA’s approval for Dronedarone Tablets

01 Feb 2024 Evaluate

Lupin has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application for Dronedarone Tablets USP, 400 mg, to market a generic equivalent of Multaq Tablets, 400 mg of Sanofi-Aventis U.S. LLC. The product will be manufactured at Lupin’s Goa facility in India.

Dronedarone Tablets USP, 400 mg, are indicated to reduce the risk of hospitalization for atrial fibrillation (AF) in patients in sinus rhythm with a history of paroxysmal or persistent AF. Dronedarone Tablets (RLD Multaq) had estimated annual sales of $510 million in the U.S. (IQVIA MAT December 2023).

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.


Lupin Share Price

2160.20 12.65 (0.59%)
23-Dec-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1814.50
Dr. Reddys Lab 1340.80
Cipla 1476.45
Lupin 2160.20
Zydus Lifesciences 972.95
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.